In this article, we will discuss Olaparib (Usage-4). So, let’s get started.
HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer
Olaparib is indicated for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate
cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Olaparib.